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Summary
Objective: Cartilage tissue engineering using multipotential human mesenchymal stem cells (hMSCs) is a promising approach to develop
treatment for degenerative joint diseases. A key requirement is that the engineered tissues maintain their hyaline articular cartilage phenotype
and not proceed towards hypertrophy. It is noteworthy that osteoarthritic articular cartilage frequently contains limited regions of reparative
cartilage, suggesting the presence of bioactive factors with regenerative activity. Based on this idea, we recently performed cDNA microarray
analysis to identify genes that are strongly expressed only in articular cartilage and encode secreted gene products. One of the genes that met
our criteria was SCRG1. This study aims to analyze SCRG1 function in cartilage development using an in vitro mesenchymal chondrogenesis
system.
Methods: Full-length SCRG1 cDNA was subcloned into pcDNA5 vector, and transfected into hMSCs and murine C3H10T1/2 mesenchymal
cells, placed in pellet cultures and micromass cultures, respectively. The cultures were analyzed by reverse transcription-polymerase chain
reaction for the expression of SCRG1 and cartilage marker genes, and by histological staining for cartilage phenotype.
Results: Induction of SCRG1 expression was seen during in vitro chondrogenesis, and was dependent on dexamethasone (DEX) known to
promote chondrogenesis. Immunohistochemistry revealed that SCRG1 protein was localized to the extracellular matrix. Forced expression of
SCRG1 in hMSCs suppressed their proliferation, and stimulated chondrogenesis in C3H10T1/2 cells, conﬁrmed by reduced collagen type I
and elevated collagen type IIB expression.
Conclusion: These results suggest that SCRG1 is involved in cell growth suppression and differentiation during DEX-dependent chondrogen-
esis. SCRG1 may be of utility in gene-mediated cartilage tissue engineering.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Cartilage
Repair
SocietyIntroduction
Normal synovial joint function is dependent on the mainte-
nance of its articular cartilage layer. Degeneration of articu-
lar cartilage results from osteoarthritis (OA) and many other
forms of severe arthritis, leading to ossiﬁcation and dysfunc-
tion of the joint1,2. OA is the most common form of arthritis
and the second most common cause of long-term disability
among adults in the United States1. Current treatments
for cartilage repair are less than satisfactory, and rarely re-
store full function or return the tissue to its native normal
state. There is thus a need for improved treatment
modalities3,4.
Tissue engineering of articular cartilage is considered to
be a promising approach to develop methods for the treat-
ment for OA and severe arthritis in patients3,4. Speciﬁcally,
multipotential human adult mesenchymal stem cells
(hMSCs) represent a candidate cell source4e7. Human
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Received 2 March 2005; revision accepted 26 July 2005.30MSCs are found in various tissues, in particular the bone
marrow, and have been shown to have the ability to differ-
entiate into multiple mesenchymal lineage, including bone,
muscle, ligament, tendon, adipose and marrow stro-
ma5,8e16. Speciﬁcally, human MSCs have also been shown
to form cartilage in vivo and in vitro9e11,14,15,17. However, it
is unknown whether this nascent cartilage tissue could re-
main hyaline and not proceed into a hypertrophy pathway
seen in endochondral skeletal tissues, and successfully ac-
quire the phenotype of articular cartilage3,18.
A number of recent studies suggest that direct application
of hMSCs may not be appropriate or adequate for the tissue
engineering of permanent articular cartilage. (1) Adult
MSCs are known to be involved in fracture healing, a pro-
cess that includes the formation of cartilaginous tissues that
undergo hypertrophy and are eventually replaced by bone
to repair the fracture2,9,11,19. This phenomenon suggests
that hMSCs may be programmed for the formation of tran-
sient cartilage destined to form bone, and unless appropri-
ately controlled, may not be a ready precursor of
permanent, articular cartilage. (2) In the developing embry-
onic limb bud, articular cartilage cells are derived from un-
differentiated mesenchymal condensation cells at very
early stage of joint formation, as a result of formation of
the inter-zone2,20,21. However, once synovial joint formation
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from mesenchymal condensation cells18,22, while chondro-
cytes derived from the remaining mesenchymal condensa-
tions will undergo hypertrophy and endochondral
ossiﬁcation22,23. This developmental pathway also sug-
gests that hMSCs in adult bone marrow may not be able
to differentiate to articular cartilage in a simple manner.
(3) Regenerated articular cartilage must be composed com-
pletely of articular chondrocytes in order to be applicable for
the treatment of diseased joints. Even a small component of
bone in the regenerated tissue could induce and worsen the
arthritic conditions. Given that hMSCs, isolated using cur-
rently available methods, do not consist of a homogeneous
cell population9,11, and the ability of hMSCs to differentiate
into osteoblasts10,12e14,16,24, modiﬁcation of hMSCs is likely
to be necessary for tissue engineering of cartilage3.
Microscopic observation of the OA articular cartilage fre-
quently shows a heterogeneous mixture of reparative carti-
lage2. It is also known that degenerated OA articular
cartilage can regenerate after high tibial valgus osteoto-
my25. These reparative reactions suggest that articular
chondrocytes may secrete bioactive factors that can induce
articular cartilage formation from progenitor cells, including
hMSCs, even in the osteoarthritic joint. Thus, we have
hypothesized that identiﬁcation and characterization of
secreted proteins from articular cartilage may lead to the
isolation of an articular cartilage inducible factor(s). It is
conceivable that transfection of such gene(s) or simple ad-
dition of the protein(s) might enable hMSCs to contribute to
the tissue engineering of articular cartilage. Based on this
idea, we have performed a comprehensive analysis of
gene-expression proﬁles in human articular cartilage and
30 other normal human tissues by means of a cDNA micro-
array consisting of 23,040 human genes26. We targeted
those genes that are strongly expressed only in articular
cartilage, and those genes whose products are secreted.
One of the genes that met both of our criteria was Scrapie
Responsive Gene 1 (SCRG1). The expression of SCRG1
in the cartilage is also conﬁrmed in 8e12 week human
fetus27.
SCRG1 is a transcript originally discovered through
identiﬁcation of the genes associated with or responsible
for the neurodegenerative changes observed in transmissi-
ble spongiform encephalopathies28. SCRG1 transcript is
detected in the brain, heart and spinal cord, and its se-
quence is highly conserved in humans, mice and rats.
SCRG1 encodes a 98 amino acid, cysteine-rich, 10 kDa
protein with signal peptide in its N-terminal, and has been
suggested to be associated with the secretory pathway of
neuronal cells29e31. The exact function of SCRG1 is still
unknown.
Glucocorticoid (GC) hormones play crucial roles in regu-
lating gene transcription. Dexamethasone (Dex) is one of
the synthetic GCs, and the molecular mechanism of Dex-
mediated transcriptional regulation has been identiﬁed in
the past decade. Dex mainly acts by binding to homodimer-
ic glucocorticoid receptor (GR) and transactivates target
genes via a glucocorticoid response element32,33. Dex is
known to induce in vitro chondrogenesis by hMSCs through
molecular mechanisms that are yet unknown34e36.
In this study, we show that SCRG1 was expressed spe-
ciﬁcally in human articular cartilage. Expression of SCRG1
was induced by Dex through the activation of GR. Forced
expression of SCRG1 suppressed growth of hMSCs and
stimulated in vitro chondrogenesis, suggesting its potential
role in mesenchymal chondrogenesis and possible applica-
tion to tissue engineering of articular cartilage.Material and methods
HUMAN TISSUE SAMPLES AND MSCs
Articular cartilage and bone marrow were obtained from
the knee joints and femoral heads of four patients (aged
from 47 to 81 years) undergoing total joint arthroplasty with
the approval of the Institutional Review Board of George
Washington University Medical School (Washington, D.C.).
Articular cartilage was shaved off from the removed joints.
Bone marrow derived hMSCs were isolated and cultured
as described previously24,37.
CELL LINES
Human mesenchymal progenitor cell line, hMPC 32F,
was established as described36. Murine C3H10T1/2 clone
cells 8 (passage 10) and monkey COS-7 cells were pur-
chased from American Type Culture Collection (Manassas,
VA). C3H10T1/2 cells were cultured and frozen stocked at
passage 11 in dimethyl sulfoxide freeze medium (IGEN
International, Gaithersburg, MD) until use. All cells were
maintained in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM; GIBCO BRL, Gaithersburg, MD) with 10% fetal bo-
vine serum (FBS; GIBCO BRL), 100 units/ml of penicillin,
100 mg/ml of streptomycin, and 25 ng/ml of Fungizone
(GIBCO) under a humidiﬁed atmosphere of 5% CO2 at
37(C. Culture medium was changed every 3e4 days.
RNA ISOLATION AND SEMI-QUANTITATIVE REVERSE
TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)
Articular cartilage samples were digested with 0.25% tryp-
sin (GIBCO BRL) in PBS for 20 min, and further digested
with 1 mg/ml of collagenase II (Worthington, Lakewood,
NJ) in DMEM containing 10% FBS at 37(C for 16 h. The di-
gest was ﬁltered with a cell strainer (BD Biosciences, San
Jose, CA) to collect chondrocytes. The chondrocytes and
hMSCs were extracted with Trizol (Invitrogen, Carlsbad,
CA) to isolate total RNA. Total RNAs of human brain, heart,
and spinal cord were obtained from BD Biosciences. A 2 mg
aliquot of total RNA was reverse-transcribed for single-
stranded cDNAs using oligo (dT)12e18 primer and Super-
script II (Invitrogen). Semi-quantitative RT-PCR was carried
out as described previously26,38,39. The primer sets (forward
and reverse) used are given below. SCRG1: 5#-TTG CTC
TGC TGC CCA AAA GAC G-3# and 5#-GAA ATC AGG
AAT GGT GTT CTC CAG-3#; mouse collagen type I (a1):
5#-ACA CTG GTA GAG ATG GTG CTC-3# and 5#-TCT
CCA GAG GGA CCC TTT TCA-3#; mouse collagen type II
(a1): 5#-GCC TCG CGG TGA GCC ATG ATC-3# and
5#-GAG GGC CAGGAGGTC CTC TGG-3#; and mouse ag-
grecan: 5#-GAG AGT TCT CAC GCC AGG TTT G-3# and
5#-TTG CCA GGG GGA GTT GTA TTC-3#. PCR reactions
were optimized for the number of cycles to ensure product
intensity within the linear phase of ampliﬁcation. The PCR
product of SCRG1 was sequenced by MTR Scientiﬁc, LLC
(Ljamsville, MD). Some of the results were analyzed by
NIH Image-J software (http://rsbweb.nih.gov/ij/).
GENERATION OF ANTIBODY FOR SCRG1 PEPTIDE
An immunogenic peptide sequence KISFVIPCNNQ-
COOH (human SCRG1 amino acid sequence: 88e98)
was synthesized by Tufts University core peptide facility
(Department of Physiology, Tufts Medical School, Boston,
MA). KLH conjugation, immunization and bleeding of
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San Francisco, CA). IgG fractions were isolated by ammo-
nium sulfate precipitation from both pre-immune and im-
mune sera.
WESTERN BLOTTING AND IMMUNOPRECIPITATION
For Western blotting, cell pellets were washed twice with
ice-cold phosphate-buffered saline (PBS), lysed with immu-
noprecipitation buffer (50 mM TriseHCl, pH 7.4; 1% Noni-
det P-40, 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM ethylenediamine tetraacetate) containing protease
and phosphatase inhibitor mixture, incubated on ice for
30 min, homogenized, and centrifuged at 14,000! g for
15 min. The supernatant was collected, and protein concen-
trations were determined using the BIO-RAD Protein Assay
(Hercules, CA). For immunoprecipitation, 1.5 ml aliquots of
culture medium were incubated with 10 ml of anti-SCRG1
antiserum, followed by addition of protein G plus agarose
(Santa Cruz Biotechnology, Santa Cruz, CA), and samples
were prepared following the manufacturer’s protocol. Equal
amounts of protein extracts were fractionated by 18%
Ready Gel TriseHCl gel (BIO-RAD), electroblotted onto Hy-
bond-P membrane (Amersham Biosciences, Piscataway,
NJ), probed with ECL anti-rabbit IgG (Amersham Bioscien-
ces), and immunoblotted using the ECL Western blotting kit
and Hyperﬁlm according to the manufacturer’s protocol
(Amersham Biosciences). Gels were stained with Coomas-
sie blue using Collidal Blue staining kit (Invitrogen) and
dried with DryEase Mini-Gel Drying system (Invitrogen).
IMMUNOHISTOCHEMISTRY
Fresh articular cartilage specimen was washed with PBS,
frozen and embedded in Tissue-Tek O.C.T. (Sakura Finetek
U.S.A. Inc., Torrance, CA) and cryosectioned at 12 mm thick-
ness. Sections were ﬁxed with 100% ethanol at 4(C for
15 min, and then rehydrated throughgradedethanol washes.
For SCRG1 detection, puriﬁed IgG preparations derived from
pre-immune serum and anti-SCRG1 antiserumwere used as
primary antibodies at 1/1000 dilution in Tris-buffered saline
with 0.05% of Tween-20 (TBS-T). Immunohistochemistry
was performed using Histostain-SP kit for DAB (Zymed Lab-
oratories) following the manufacturer’s protocol.
Gene transfected cells were cultured on Labtek Perma-
nox chamber slides (Nunc, Naperville, IL) for 48 h, washed
with PBS and ﬁxed with methanol for 10 min, preincubated
with blocking solution (4% bovine serum albumin in TBS)
for 1 h at room temperature, and incubated for 2 h at room
temperature with anti-SCRG1 IgG diluted 1:1000 in block-
ing solution. Immunostaining was visualized with a donkey
anti-rabbit Alexa Fluor 488 conjugated IgG (Molecular
Probes, Eugene, OR) and observed using a Leica DM IL
microscope (Leica Cameras Inc., Northvale, NJ).
CELL PROLIFERATION ASSAY
The PCR ampliﬁed full-length cDNA sequences of GFP
and SCRG1 cDNA were inserted into pcDNA5/FRT vector
(Invitrogen) and designated as pcDNA-GFP and pcDNA-
SCRG1, respectively. Human MSCs and C3H10T1/2 cells
were transfected with pcDNA-GFP vector or pcDNA-
SCRG1 using human MSC nucleofector kit (Amaxa Biosys-
tem, Gaithersburg, MD)40. Brieﬂy, 1! 106 of trypsinized
hMSCs was suspended with 100 ml of Human MSC Nucle-
ofector Solution and 2 mg of plasmid DNA. The suspensionwas electroporated with the Amaxa Nucleofector U-23 pro-
gram, and then maintained in DMEM with 20% FBS over-
night. The next day, the transfected cells were cultured in
DMEM with 10% steroid-stripped FBS (ss-FBS; charcoal/
dextran treated fetal bovine serum; Hyclone, Logan, UT)
containing 0.1 mg/ml (hMSCs) or 0.4 mg/ml (C3H10T1/2
cells) of G418 (GIBCO BRL) for a week. C3H10T1/2 cells
were transfected using Lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer’s protocol. After 1 week of cul-
ture, 1.8! 104 of viable, transfected cells were plated in
24 well plates with DMEM containing 10% ss-FBS and
10 mg/ml of G418 for further analysis. Counting of viable
cells was performed either by direct cell counting after Try-
pan Blue staining (Bio WHITTAKER, Watersville, MD) or
by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay using Cell-
Titer 96 Aqueous One Solution Cell Proliferation Assay
(Promega, Madison, WI) according to the manufacturer’s
suggestions.
IN VITRO CHONDROGENESIS
For C3H10T1/2 cells, the high-density micromass culture
technique was carried out according to Denker et al.41
C3H10T1/2 cells were used at passage 11 from frozen
stocks of less than 3 months. One day after transfection
with either pcDNA-GFP vector or pcDNA-SCRG1 using hu-
man MSC nucleofector kit, cells were trypsinized, counted,
and plated as 10 ml drops at 1! 107 cells/ml in Ham’s F12
medium with 10% of ss-FBS onto 24-well polystyrene tissue
culture dish. After adherence for 1.5 h at 37(C and 5% CO2,
the cells were fed 1 ml of Ham’s F12 medium with 10% ss-
FBS and 100 ng/ml of human recombinant bone morphoge-
netic protein-2 (BMP-2) (R&D system, Minneapolis, MN).
The culture medium was changed every 3e4 days until fur-
ther analysis.
For hMSCs, the pellet culture was performed with hMPC
32F as previously described24,42. Brieﬂy, 0.25! 106 cells
were pelleted by centrifugation and maintained in a se-
rum-free medium containing 0.1 mM DEX, 50 mg/ml L-ascor-
bate 2-phosphate, 40 mg/ml L-proline, 100 mg/ml sodium
pyruvate (Sigma), ITS-Premix (BD Biosciences, Bedford,
MA), and 10 mg/ml transforming growth factor-b3 (TGF-b3,
R&D Systems, Inc., Minneapolis, MN). In selected cultures,
the GC antagonist, RU-36846 (Sigma), was added at
10 mM to the medium.
HISTOLOGICAL ANALYSIS OF CHONDROGENESIS
The presence of sulfated proteoglycans indicative of car-
tilage formation was detected by alcian blue staining43. Mi-
cromass cultures of C3H10T1/2 cells were washed in PBS,
ﬁxed in 2% acetic acid in ethanol for 15 min and rehydrated
with graded ethanol. Sulfated cartilage matrix was visual-
ized by overnight staining with 0.5% Alcian blue 8GX
(pH 1) (Sigma, St. Louis, MO). Alcian blue was quantiﬁed
by measuring absorbance of the extracted dye at 595 nm
as described previously44. Each experiment was repeated
at least three times using triplicate samples, and results pre-
sented as meanG S.D.
STATISTICAL ANALYSIS
Numerical data were analyzed for statistical signiﬁcance
using Student’s t test with a conﬁdence level of 95%
(P! 0.05). All values are reported as meanG S.D.
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SCRG1 EXPRESSION IN ARTICULAR CARTILAGE
Our previous microarray data suggested that SCRG1 is
expressed at a very high level only in articular cartilage26.
On the other hand, SCRG1 has also been suggested to
be expressed in spinal cord, brain and heart29. To better ac-
cess the human tissue expression proﬁle of SCRG1, we
performed semi-quantitative RT-PCR to compare the ex-
pression of SCRG1 among the tissues purported to express
SCRG1 [Fig. 1(A)]. Our results showed that articular carti-
lage and spinal cord expressed SCRG1 at the highest level.
Interestingly, the level of SCRG1 expression in hMSCs was
approximately the same as that in brain and heart tissues.
LOCALIZATION OF SCRG1 IN VITRO AND IN VIVO
To assess the distribution of SCRG1 protein in human ar-
ticular cartilage, we prepared antisera against a SCRG1
peptide sequence predicted to be hydrophilic and antigenic.
To conﬁrm the speciﬁcity of the anti-SCRG1 antibody, we
performed Western blotting using extracts of C3H10T1/2
cells transfected with pcDNA5-GFP and pcDNA5-SCRG1
constructs. As shown in Fig. 1(B), an immunoreactive
10 kDa band was detected in pcDNA5-SCRG1 transfectedcells, but not in pcDNA5-GFP transfected cells. Incubations
with pre-immune serum also did not show any immunoreac-
tive band in either pcDNA5-GFP or pcDNA5-SCRG1 trans-
fected cells (data not shown). Taken together, these results
indicate the reactivity and speciﬁcity of the anti-SCRG1 anti-
bodies. To examine whether SCRG1 was produced as a se-
creted protein, we performed immunoprecipitation of culture
media of GFR-transfected and SCRG1-transfected
C3H10T1/2 cells. As shown in Fig. 1(C), SCRG1 was de-
tected only in the culture medium of SCRG1 transfected
cells, suggesting that SCRG1 is produced as a secreted
protein.
To determine the subcellular localization of SCRG1 pro-
tein in mesenchymal cells, C3H10T1/2 cells transfected
with pcDNA5-GFP and pcDNA-SCRG1 were analyzed by
ﬂuorescence immunohistochemistry. The micrograph
[Fig. 1(D)] showed that SCRG1 protein is localized in cyto-
plasmic granules, consistent with the secretory nature of
SCRG1 protein production.
Enzyme-based immunohistochemistry revealed that
SCRG1 protein was also present in human adult articular
chondrocytes in vivo [Fig. 1(E, F)]. The immunostaining ap-
peared to be localized to the pericellular matrix surrounding
the articular chondrocytes, especially within the lacunae.
Interestingly, SCRG1 protein was well detected in the
intermediate zone of articular cartilage.Fig. 1. SCRG1 expression in vitro and in vivo. (A) Semi-quantitative RT-PCR of SCRG1 in human tissues. RT-PCR was performed using
RNAs of human brain, heart, spinal cord, articular cartilage and hMSCs. GAPDH was used as an internal control. Sequencing was performed
to conﬁrm the PCR products. Articular cartilage and spinal cord expressed SCRG1 at the same level, indicating that articular cartilage was one
of the highest SCRG1-expressing tissues in human. BR, brain; HT, heart; SC, spinal cord; AC, articular cartilage. (B) Western blotting of
pcDNA5-GFP and pcDNA5-SCRG1 transfected C3H10T1/2 cells. Ectopic expression of SCRG1 in C3H10T1/2 cells was detected by Western
blotting (pre-immune IgG used as control). The arrow indicates the presence of 10 kDa SCRG1 band only in the SCRG1 transfected cultures
upon reaction with immune IgG. (C) Immunoprecipitation of culture medium of GFP vector or SCRG1 transfected cells, showing the presence
of SCRG1 (arrow) within culture medium of only the SCRG1 transfected cells. (D) Immunoﬂuorescence of SCRG1 transfected C3H10T1/2
cells showing the localization of the protein in cytoplasmic granules. (E,F) SCRG1 immunohistochemistry of human articular cartilage. Anti-
serum directed against immunogenic peptide sequence of SCRG1 protein (KISFVIPCNNQ-COOH) was used. Human adult articular cartilage
was stained either with pre-immune serum (E) or anti-SCRG1 serum (F). Both articular chondrocytes and the extracellular matrix surrounding
their lacunae were positively stained. Magniﬁcation: barZ 25 mm (D) and 100 mm (E,F).
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To investigate whether SCRG1 was expressed during
mesenchymal chondrogenesis, we performed RT-PCR of
SCRG1 using chondrogenic pellet culture of hMSCs. As is
shown in Fig. 2(A), the expression of SCRG1 was induced
in a time dependent and Dex/TGF-b3 dependent manner.
By Day 21, the expression of SCRG1 increased to a level
similar to that detected in articular cartilage. To analyze
the dependence of the SCRG1 induction on Dex and/or
TGF-b3, these two reagents were added separately to the
culture medium. RT-PCR analysis revealed that addition
of Dex alone could induce SCRG1 expression [Fig. 2(B)],
i.e., the induction was not enhanced by addition of TGF-b3
to Dex supplemented medium. To investigate whether this
induction was mediated by the GR, we tested the effect of
RU-36846 on the culture. RU-36846 completely inhibited
the induction of SCRG1 on Day 11; however, RU-36846
could not completely inhibit the induction on Day 21
[Fig. 2(C)].
SCRG1 EXPRESSION SUPPRESSED PROLIFERATION
OF hMSCs
As articular cartilage is an avascular tissue, articular
chondrocytes are not normally exposed to serum in vivo2.
To determine whether the presence of serum could affect
SCRG1 expression during chondrogenesis, we added
10% FBS to the otherwise serum-free chondrogenic culture
medium of hMSCs. As shown in Fig. 3(A), addition of FBS
suppressed the induction of SCRG1. As one of the effects
of serum is the enhancement of cell proliferation, we next
tested the involvement of SCRG1 in the regulation ofmesenchymal cell proliferation. MTS analysis revealed that
forced expression of SCRG1 in hMSCs suppressed cell
growth in a time dependent manner [Fig. 3(B)]. We have al-
so transfected C3H10T1/2 cells with GFP and SCRG1 vec-
tors using either Nucleofector or Lipofectamine 2000, and
assayed cell growth rate by direct cell counting and MTS
assay, and obtained similar results (data not shown). These
results suggest that SCRG1 may play a role in the regula-
tion of mesenchymal cell growth.
SCRG1 EXPRESSION STIMULATED CHONDROGENESIS
IN VITRO
We next investigated the effect of forced SCRG1 expres-
sion during the early events of mesenchymal chondrogene-
sis in vitro. High-density micromass cultures of
mesenchymal cells, including limb bud cells and murine
C3H10T1/2 cells, have been shown to undergo chondro-
genesis in vitro41,45e48. In this study, C3H10T1/2 cells were
transfected either with pcDNA-GFP or pcDNA-SCRG1, and
treated with 100 ng/ml of BMP-2. In this culture system,
most chondrogenic cell condensations eventually devel-
oped into cartilaginous nodules, which could be identiﬁed
by alcian blue staining. After 5 days of culture, both trans-
fected groups showed small round cells with metachromatic
borders, whose morphology resembled early chondrocytes
in culture as described previously41,49. Although chondro-
genesis was seen in both GFP vector and SCRG1 trans-
fected cell cultures, transfection of SCRG1 resulted in
a signiﬁcant increase in alcian blue staining when com-
pared with GFP vector transfected controls [Fig. 4(A, B)].
Although less evident as on Day 5, the difference in alcianFig. 2. RT-PCR analysis of SCRG1 expression in in vitro chondrogenic pellet culture. (A) Expression levels of SCRG1 are dependent on time
and on Dex and TGF-b treatment as shown in the Day 0, Day 9 and Day 21 samples. Note that the level of expression of SCRG1 on Day 21 is
similar to that in articular cartilage. AC, articular cartilage. (B) Dex treatment is sufﬁcient to induce SCRG1 expression. Either Dex alone or
Dex/TGF-b3 was added to the culture medium. RT-PCR revealed that addition of Dex alone could induce SCRG1 expression on Day 11,
and that this induction was not further enhanced by the addition of TGF-b3. (C) Dex-mediated induction of SCRG1 is modulated via GR action.
Co-treatment with the glucocorticoid inhibitor, RU-36846, completely inhibited Dex induced SCRG1 expression by Day 11. However, by Day
21, RU-36846 was less effective.
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persisted on Day 14 [Fig. 4(A, B)]. In the absence of
BMP-2, neither GFP vector nor SCRG1 transfected micro-
mass culture showed alcian blue staining (data not shown),
suggesting that the action of SCRG1 alone may not be able
to induce chondrogenesis in vitro. The role of SCRG1 could
be the enhancement of cartilage development, perhaps in
the synthesis and deposition of extracellular matrix.
SCRG1 mediated enhancement of chondrogenesis was
also conﬁrmed by RT-PCR analysis of the expression of
chondrocyte markers. As shown in Fig. 4(C), expression
of pre-chondrocyte markers (collagens type I and type IIA)
was slightly reduced, while that of differentiated chondro-
cyte markers (collagen type IIB and aggrecan) was slightly
elevated. These changes were apparent especially during
the early stages of chondrogenic differentiation. (Note
that gene-expression levels of collagen type IIA, the alterna-
tively spliced mRNA isoform associated with pre-cartilage
mesenchyme, were undetectable on Days 10 and 14.)
Discussion
We report here that a GC inducible gene SCRG1, which
was expressed normally at high levels in articular cartilage,
could suppress cell growth and stimulate in vitro chondro-
genesis in high-density micromass culture of mesenchymal
cells, such as C3H10T1/2 cells. Evidence for the high level
of expression of SCRG1 in articular cartilage was obtained
through comparison of SCRG1 transcript levels between
SCRG1-expressing tissues [Fig. 1(A)]. It has been previ-
ously shown that SCRG1mRNA is expressed at the highest
level in spinal cord. Using a membrane blotted with poly
(A)C RNA from 50 human tissues, the level of SCRG1 tran-
script was shown to be more than 2 fold higher than any
other tissues29. On the other hand, our previous work
Fig. 3. Effect of SCRG1 on the proliferation of hMSCs. (A) SCRG1
expression in hMSCs is modulated by the presence of serum in cul-
ture medium. Cells were cultured in chondrogenic culture medium
either with or without 10% ss-FBS. Addition of FBS suppressed in-
duction of SCRG1 in hMSCs. (B) SCRG1 suppresses hMSC prolif-
eration. Forced expression of SCRG1 in hMSCs suppressed cell
growth in a time dependent manner, based on MTS assay. nZ 6;
*P! 0.05, when compared with GFP.comparing 31 human tissues using microarray suggested
that articular cartilage expressed SCRG1 at the highest
level26. To better access which tissue is in fact expressing
SCRG1 at the highest level, we have performed here
semi-quantitative RT-PCR of ﬁve human tissues, articular
cartilage, spinal cord and other SCRG1-expressing tissues.
As shown in Fig. 1(A), comparable highest level of SCRG1
expression was seen in articular cartilage and spinal cord,
indicating that articular cartilage was indeed among the
highest SCRG1-expressing tissues in human.
Immunoﬂuorescence analysis of SCRG1 transfected cell
showed that SCRG1 protein is localized in cytoplasmic
granules in C3H10T1/2 cells. Western blotting showed an
immunoreactive protein of about 10 kDa in size, and immu-
noprecipitation analysis showed that this protein was actu-
ally secreted into media. These properties of SCRG1
protein in mesenchymal cells are similar to those observed
for neuronal cells31. In addition, immunohistochemistry of
human adult articular cartilage, as shown in Fig. 1(E),
showed the presence of SCRG1 protein in the extracellular
matrix within the lacunae of articular chondrocyte. Taken to-
gether, these observations suggest that SCRG1 protein
was secreted in vivo by articular chondrocytes and de-
posited within their immediate extracellular matrix.
Dex is known to induce in vitro chondrogenesis in mesen-
chymal progenitor cells7,11,34,35,50, but its exact molecular
mechanisms are still unknown. We have shown here that
SCRG1 expression was induced in a Dex-dependent man-
ner during in vitro chondrogenic pellet culture of hMSCs.
This SCRG1 induction by Dex is mediated via GR during
the earlier stage of chondrogenesis (Day 11). In the later
stage of chondrogenesis (Day 21), the Dex antagonist,
RU-36846, failed to inhibit SCRG1 expression completely.
These ﬁndings suggest that SCRG1 expression is regu-
lated by the Dex-GR pathway during the early stages
of chondrogenesis.
Dex is known to suppress cell growth during pre-chondro-
genic and chondrogenic period of murine multipotential mes-
enchymal cell line ATDC5, but the exact molecular
mechanisms are not known50. We have also recently ob-
served similar growth suppression by addition of Dex to un-
differentiated hMSCs (Derfoul et al., in preparation). Our
ﬁnding here that SCRG1 is Dex-inducible and is capable of
suppression of cell proliferation of hMSCs and C3H10T1/2
cells suggests that SCRG1may be one of the key molecules
in Dex-mediated mesenchymal cell growth suppression.
BMP-2 is a key inducer of chondrogenesis for in vitro
chondrogenesis system in micromass culture of
C3H10T1/2 cells41. In cultures of both C3H10T1/2 cells
and hMSCs, BMP-2 up-regulates Sox-9 in a dose depen-
dent manner51e53. Sox-9 is a high mobility group domain
transcription factor expressed in all cartilage primordia dur-
ing embryogenesis, and is believed to play a key regulatory
role in chondrogenesis54. We have shown here that SCRG1
expression alone could not induce chondrogenesis, but in
the presence of BMP-2, SCRG1 transfected cells yielded
signiﬁcant increase in alcian blue staining, compared to
control, GFP vector transfected cells. These data suggest
that SCRG1 can enhance events downstream of BMP-2
action. This effect was not mediated through BMP-2 modu-
lation of the Sox-9 pathway, since RT-PCR analysis
showed no detectable differences in Sox-9 level in control,
SCRG1 or GFP vector transfected micromass cultured
cells. SCRG1 enhancement of chondrogenesis is thus likely
to act either independent of Sox-9 or downstream of Sox-9
activation. Given that SCRG1 was induced as early as Day
3 in chondrogenic pellet culture [Fig. 3(A)], whereas Sox-9
36 K. Ochi et al.: Glucocorticoid-inducible SCRG1 stimulates chondrogenesisFig. 4. Acceleration of in vitro chondrogenesis by SCRG1 expression in high-density micromass cultures of C3H0T1/2 cells. (A) Alcian blue
staining of cartilage matrix. In control cultures transfected with GFP construct, matrix produced by the micromass culture became alcian blue
positive by Day 5, and was highly evident by Day 14. SCRG1 transfected micromass culture appeared more strongly stained than the control
throughout the same time course. Scale bar: 1 mm. (B) Quantitation of alcian blue staining. Signiﬁcant increase in alcian blue staining was
observed in SCRG1-transfected cultures compared to the control. nZ 6; *, P! 0.05 when compared with GFP. (C) Gene expression ana-
lyzed by semi-quantitative RT-PCR. The level of pre-chondrocyte markers (collagen type I and type IIA) decreased, while the level of differ-
entiated chondrocyte markers (collagen type IIB and aggrecan) increased upon forced expression of SCRG1. These changes were apparent
especially during the early stages of chondrogenic differentiation. (Note that gene-expression levels of collagen type IIA, the alternatively
spliced mRNA isoform associated with pre-cartilage mesenchyme, were undetectable on Days 10 and 14.) Expression levels were normalized
to GFP transfected C3H10T1/2 cells at each time points. nZ 3; *P! 0.05, when compared with GFP.was not induced until after Day 7 in the same culture sys-
tem55, the SCRG1 mediated enhancement of chondrogen-
esis is likely to be independent of Sox-9 pathway, rather
than acting downstream in Sox-9 mediated
chondrogenesis.
Concerning the time course of the effect of SCRG1
forced expression on chondrogenesis, it is noteworthy thatculture Day 9 corresponds approximately to the time point
when pellet cultures of hMSCs start to chondrify and be-
come alcian blue positive, i.e., the early phase of chondro-
genesis. Similarly, in the C3H10T1/2 micromass cultures,
SCRG1 also appears to play a stimulatory role in accelerat-
ing early chondrogenesis. Given that in both systems, other
effectors, i.e., DEX or BMP-2, are required, the exact
37Osteoarthritis and Cartilage Vol. 14, No. 1mechanism of action of forced expression of SCRG1 on
other early phase chondrogenesis, particularly related to
the other effectors, remains to be elucidated.
Another issue related to SCRG1 stimulation of chondro-
genesis in micromass cultures of C3H10T1/2 cells is that
alcian blue staining increased considerably higher than ag-
grecan gene expression [Fig. 4(B, C)]. The most likely ex-
planation is that gene-expression level was assessed by
non-quantitative RT-PCR, which may not directly correlate
to the level of sulfated proteoglycan produced, detectable
by alcian blue staining. Other possibilities may include in-
creased level of sulfation itself, and the production of other
sulfated proteoglycans apart from aggrecan. In any event,
the acceleration of chondrogenesis in early chondrogenesis
(Day 5) is also supported by the changes in the expression
level of collagen type I and collagen type IIB.
Although Dex can induce in vitro chondrogenesis in pellet
culture of mesenchymal stem cells, it is not a speciﬁc chon-
drogenic differentiation factor. Dex can induce hMSCs to
differentiate into osteoblasts, myoblasts and adipocytes
depending on speciﬁc culture conditions35. As for chondro-
genesis, the effect of Dex differs depending on the differen-
tiation stage of the chondroprogenitor cells50. Thus,
identifying chondrogenesis-speciﬁc genes downstream of
Dex action would be of great value to cartilage tissue
engineering as well as provide insights into the biology of
skeletal development.
It is also well known that clinical use of GCs has severe
side effects, including growth retardation and osteoporosis.
Repeated articular injection of Dex potentially worsens OA
by accelerating cartilage degradation56. These side effects
severely limit the application of Dex for skeletal tissue engi-
neering. Ideally, if SCRG1 could produce the chondrogenic
effect of Dex without its side effects, SCRG1 should be of
great utility in gene-based cartilage tissue engineering. Fur-
ther investigation of the role in chondrogenesis should shed
light on the molecular mechanisms involved in skeletal tis-
sue development, repair and tissue engineering.
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